geneity of these prevalence estimates was observed. Conclusions: APOE e4 genotype prevalence varies among AD patients by region and within each country. Further exploration is warranted to better understand the substantial heterogeneity of these prevalence estimates.
Introduction
Alzheimer's disease (AD) is the most common form of dementia, and recent prevalence estimates suggest it impacts the lives of 4.4% of the population over 65 years old [1] . Apolipoprotein E (APOE) e4 has been recognized as a genetic risk factor for developing late-onset AD for over two decades [2] [3] [4] . Carriers of two APOE e4 alleles (homozygotes, e4/4) have a higher risk and also earlier onset of AD than heterozygous carriers (e4/-) [2, 4] . However, late-onset AD is believed to be caused by multiple other genetic and environmental factors that are not yet completely identified, and the interactions between these are not yet well understood [5] . Some researchers have suggested contemporary environmental conditions may have led APOE e4 carriers to have an increased suscepti-2 bility to developing AD, such as high intake of carbohydrates and fat, low fiber, and reduced physical activity [6] .
The APOE gene is polymorphic, with three common alleles (e2, e3, e4), and in studies of the general population, a substantial amount of variation has been consistently observed by geographic location in the six genotypes: 3/3, 4/3, 3/2, 4/4, 4/2, and 2/2 [7] . APOE e3 is the most frequent [7] . APOE e4 is consistently observed to be more common in the general population residing in Northern Europe than in the Mediterranean regions of France and Italy, or in Asia [6] [7] [8] . The purpose of conducting this literature review is to summarize the published evidence on the prevalence of the APOE e4 genotype (e4/-) and homozygotes (e4/4) among patients diagnosed with AD. Specifically, published estimates of APOE e4 homozygote and heterozygote prevalence in observational studies were tabulated and reported for each country. Estimates for APOE e4 carrier prevalence were then derived for Asia, Europe (Central, North, and South/ Mediterranean), North America, and South America.
Methods
A protocol was developed and followed for each of the steps of this review, and the methods used for this review followed current practices for conducting systematic reviews and meta-analyses of the literature. The data source for this project was the literature published between January 1, 1985, and May 31, 2010. The literature search was performed using both electronic and manual components. MEDLINE (via PubMed) and EMBASE were searched to identify English-language studies published within the past 25 years. The searches were conducted using a combination of search terms and key words for apolipoproteins, APOE4, and AD and terms related to the study design, such as observational, community-based, population, cross-section, epidemiological, longitudinal, prospective, cohort studies, and cross-sectional studies. Case reports, letters, commentaries, editorials, reviews, clinical trials, meta-analyses, practice guidelines, and in vitro studies were excluded. The search terms and strategies were developed in consultation with a medical librarian, and each search strategy was adapted to the idiosyncrasies of each of these databases by using the appropriate index structures (e.g. Medical Subject Headings -MeSH in MEDLINE and EMTREE in EMBASE). The searches included limits for English language and human subjects. A manual check of the bibliographies of each of the articles included in the analysis was also performed to identify additional potentially relevant material and supplement the electronic searches.
Citations and abstracts of all studies identified in the searches were downloaded and the duplicates removed; study selection was based on 2 levels of screening. Initially, the title and abstract of each citation were screened based on the prespecified inclusion and exclusion criteria in the protocol. Articles deemed potentially eligible were then retrieved, and the full text was screened by 2 independent reviewers to determine whether it met the eligibility criteria. All disagreements were resolved by consensus.
The eligible articles were observational studies (clinic or community-based samples) with 30 or more adults diagnosed with AD reporting APOE e4 genotype data at the baseline of a cohort study, case-control study, or cross-sectional survey. Autopsy studies were excluded. Accepted articles describing the same AD population ('kin studies') were identified by reviewing the method section, geographic location, sample sizes, and author or institution names, and a single citation for each independent sample of patients diagnosed with AD was included in the analysis to avoid double-counting the results from the same population.
Data were extracted by one researcher and verified by another, and any differences were resolved by consensus. Information was extracted from each included study on country, geographic location, sources of cases (clinic, community, other), study design (cross-sectional, case control, or cohort), AD case definition, subclasses (early, late onset, sporadic, familial, mixed), and demographics (gender, race, age). The frequency of the APOE e4 genotype and, when reported, e4/4 status stratified by AD case definitions were extracted for each study.
APOE e4 and e4/4 Prevalence
Study characteristics and subject level data were first summarized using SAS version 9.1 (SAS Institute, Cary, N.C., USA) to calculate basic descriptive statistics organized by country and geographic region. The prevalences of ApoE e4 (%) and e4/4 (%) were computed using restricted-maximum likelihood varianceweighted random effects meta-analyses [9, 10] that were conducted on the APOE e4 carrier and e4/4 proportions overall and by AD case definition. For this analysis, the term 'probable AD cases' is applied only to the samples specifically reported as meeting the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for 'probable' AD. AD cases were defined as possible when reported as 'possible' by the authors, identified as AD patients with no additional criteria, or reported as a mixed population of 'possible' and 'probable' cases.
Heterogeneity (between-study inconsistency) was investigated and measured using Cochran's Q statistic and the I 2 statistic [11] . Cochran's Q, distributed as a 2 statistic, estimates heterogeneity as the weighted sum of squared differences in effects across pooled studies. I 2 estimates what percentage of interstudy variability is due to heterogeneity rather than to chance. As significant heterogeneity was present, the variation was investigated further by conducting stratified analyses and meta-regression. First, stratified analyses were performed by region and by country and AD case definition where there were at least 3 studies to pool. Next, age, AD case definition (probable AD vs. other), sample population source (community vs. other), and study design (case control vs. other), as predictors for regional APOE e4 and e4/4 prevalence, were explored using random effects meta-regression [12] . For countries with adequate numbers of studies, the impact of sampling from AD populations residing in different areas within the country was also explored. If there were too few studies within a given region or country, meta-regression was not performed. Each variable was converted to binary categories and modeled simultaneously. The age category was defined as below or above the age in the lowest quartile of the average age of all the studies. Variables found to explain heterogeneity were also applied individually to regional and country estimates to explain variance.
Results

Study Selection
Titles and abstracts from a total of 1,492 articles were screened, and 722 full-text articles were reviewed (see fig. 1 for additional details on each step). The reasons for exclusion were no APOE data reported or not reported separately for adult AD patients, study sample size fewer than 30 subjects, or autopsy study. A total of 258 articles met our eligibility criteria, of which 139 were identified as reporting APOE e4 data from 142 independent samples of patients diagnosed with AD. Four studies reported on more than 1 patient population; these groups, as well as the 'parent' studies, were considered as 2 distinct populations for the purpose of analysis. The full study listing of the 139 articles reporting the data included in the analysis is provided in the Appendix. In addition, 73 of these independent samples of patients diagnosed with AD also provided data on the prevalence of APOE e4/4.
Study Characteristics
The studies analyzed included a combined 27,109 individuals with a mean age of 75.2 years (range: 63.0-89.0); 64.1% were female. Fifty-eight percent (15,773 participants) were diagnosed as 'probable' AD cases. Thirty-one were described clearly as community-based samples (4,040 individuals), the majority were clinic-or hospitalbased samples (18,500 individuals), and the others were not possible to classify or were a combination. The analysis was conducted with separate estimation of the prevalence for 6 predefined geographic regions: Asia, Europe (Central, North, and South/Mediterranean), North America, and South America. As the region Oceania only included 1 country, Australia, this is reported with other country-specific analyses. Information from each study included in the analyses is provided for each region in tables 1-3 . Regional Estimates An overview of the variation across 6 geographic regions is presented graphically in figure 2 . The metaanalysis estimates and tests for heterogeneity are provided in tables 1-3 . As has been observed in the general population, the prevalence varied by geographic location, with the lowest regional estimates for the prevalence of e4 carriers in Asia: 41 * Significant heterogeneity at p < 0.10; ** significant heterogeneity at p < 0.01. NR = Not reported. 
Country-Specific Estimates
Fifteen countries had more than 3 studies and, for these 15 countries, the data were pooled for each country ( table 6 ). Substantial within-region variation was evident; for example, in Asia the point estimate and 95% CI for Japan were 48.9% (95% CI: 45.9-51.9), and for China they were 32.8% (95% CI: 28.3-37.3). Substantial heterogeneity of the majority of these country-specific prevalence estimates was observed, as indicated by a value of I 2 greater than 50% for all the countries except 4 -Canada, France, South Korea, and Spain. Subgroup analyses were conducted to explore sources of heterogeneity by AD case definition ( table 7 ) . The probable cases generally had higher estimates within each country, although there was substantial heterogeneity in the study results.
Variation within Countries
Analyses were also conducted to explore sources of heterogeneity within Italy, Japan, and the USA, as ade- 
Meta-Regression
As significant heterogeneity was present, the variation in each geographic region was explored using metaregression. Although meta-regression can adjust for the effect of study level characteristics on the results, the factors should be commonly reported at the study level, and this limits the factors that can be considered in these analyses. In the meta-regression analyses for APOE e4 carrier prevalence in Asia and North America, the AD case definition significantly contributed to the heterogeneity of the regional results, although this was not ob- served for all regions. In the analyses of North America, AD case definition, community studies, and age ^ 75 years contributed to the heterogeneity. None of the variables included in these analyses consistently explained the heterogeneity among all the APOE e4 regional results. As significant heterogeneity was present, the variation in estimates from Italy, Japan, and the USA was explored using meta-regression and included location within a country (e.g. North vs. South). None of the variables for different areas within a country included in these analyses explained the heterogeneity among the results in these 3 countries.
In the meta-regression analyses for APOE e4/4, none of the variables included in these analyses explained the heterogeneity in any of the geographic regions or in Italy, Japan, and the USA.
Discussion
This study summarizes the APOE e4/4 homozygote and e4/-carrier prevalence data published since 1985, and pools the genetic data collected from 27,109 patients diagnosed with AD residing in 33 countries. Prevalence estimates are reported for AD populations worldwide, including populations residing in Europe (North, Central, * Significant heterogeneity at p < 0.10; ** significant heterogeneity at p < 0.01. * S ignificant heterogeneity at p < 0.10; ** significant heterogeneity at p < 0.01. * Significant heterogeneity at p < 0.10; ** significant heterogeneity at p < 0.01.
and South/Mediterranean), Asia, North America, and South America. Enough studies have been conducted in 9 countries (Australia, China, France, Germany, Japan, Italy, Spain, the UK, and the USA) to also develop country-specific estimates.
The meta-analysis results suggest that heterogeneity within geographic locations and AD definitions is not fully explained by variation in the source of the patient sample, study design, or mean age of the individual study population. The potential for selection bias has to be considered, as the frequency of the APOE e4 allele has been observed to be lower in community-based AD patient samples than in research clinics, trials, or autopsy studies [13, 14] . This review excluded trials and autopsy studies, but it should be noted that almost two thirds of the participants included in the analysis were recruited while attending a clinic. This analysis also could not consider the factors influencing why some patients volunteer for this genetic test. There can be genetic heterogeneity within areas of a country, and some studies may select a specific or non-representative population; for example, Bowirrat et al. [15] conducted a door-to-door survey of elderly Arabs residing in a certain area of Israel (Wadi Ara). Although differences in AD case definitions contribute to the substantial heterogeneity of published prevalence estimates within each region, the variables included in these analyses could not explain the heterogeneity observed in the published estimates. Meta-regression can adjust for the effect of study level characteristics on the results, but relatively few factors were commonly reported at the study level, and this limited the factors able to be considered in this analysis. For example, race was not recorded in many studies, and the ability to fully explore age was limited to the mean age reported in the publications. Although the reasons for the substantial heterogeneity were not possible to elucidate from this review, caution is warranted when attempting to infer regional or country-specific estimates of the ApoE e4 allele frequency. Such differences may arise from small-area variations in allele frequency, environmental risks that vary between regions, methodologic differences, or a combination. The heterogeneity limits the ability to incorporate allele frequencies into models forecasting AD incidence and prevalence estimates and may hinder health policy planning efforts related to allele frequency.
The pooled estimate for APOE e4 carrier prevalence was 48.7% (95% CI: 46.5-51.0), and homozygote (e4/4) prevalence was 9.6% (95% CI: 8.4-10.8). However, there was substantial heterogeneity in these prevalence estimates. In 1997, Farrer et al. [4] published somewhat high- Prevalence of APOE e4 and e4/4, meta-regression coefficients by region er prevalence estimates (e4/-: 58.5% and e4/4: 14.8%) from a pooled analysis of data, provided by 40 research teams, that had been collected from 5,107 'Caucasian' patients diagnosed with probable or definite AD. The lower estimates in the current study could perhaps be anticipated as approximately one third of the cases are from Asia, where APOE e4 prevalence is lower in the general population, and autopsy studies were excluded. The lowest regional estimates for e4 carrier status were observed in Asia (41.9%; 95% CI: 38.5-45.3) and Southern Europe (40.5%; 95% CI: 36.8-44.1), where the majority of AD cases were not APOE e4 carriers. In marked contrast, the majority of cases in Northern Europe were carriers (61.3%; 95% CI: 55.9-66.7). Similar patterns were observed for APOE e4/4 estimates. These trends are consistent with general population studies in which the APOE e4 frequencies were observed to be higher in Northern than in Southern Europe or Asia, and to be lowest in Italy, Japan and Korea [6] [7] [8] . Substantial heterogeneity of the estimates was observed within each region and remained when additional analyses pooled the estimates by country or, in some cases, by areas within each country.
When the analyses were stratified by AD case definition, graphically there was a general trend within each region for a higher prevalence in the studies selecting 'probable' AD cases. In the meta-regression analysis for Asia, North America, and Australia, the case definition contributed to the heterogeneity of these regional results, although this was not observed for all regions. For this analysis, the term 'probable' AD case is applied only to the samples specifically reported as meeting the NINCDS-ADRDA criteria. The differences in AD case definitions are therefore likely to be contributing to the heterogeneity observed in the published prevalence estimates, especially as not all the studies specified the criteria applied. This review identified studies conducted in this field during the last 25 years, and each of the researchers applied the current clinical diagnostic criteria for AD; however, in the future, biomarkers for AD will increasingly be used to support diagnoses in research settings [16] , and this has the potential to improve the design of studies in this field.
Genotyping results stratified by familial AD, sporadic AD, early-onset AD, and late-onset AD were extracted when reported. However, the number of studies reporting these specific categories was insufficient to conduct analyses by region. Although differences in the genetic susceptibility for these different clinical presentations of AD may explain in part the substantial amount of interstudy heterogeneity demonstrated across every analysis, this could not be explored in this project.
Although APOE e4 is a well-studied genetic risk factor for developing AD, in some regions most patients do not carry this genotype, and additional research is needed to be able to understand both other genetic and environmental risk factors. Currently, genetic testing of APOE e4 carrier status is not routinely considered in clinical practice. However, if the mechanism of action of new products for preventing the progression of AD is contingent on a patient's APOE e4 carrier status, then there may be regions where testing could be essential to consider both during drug development and postmarketing. 
